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LGR4/5 receptors and their cognate RSPO ligands potentiate Wnt/β-Catenin signalling 1 
and promote proliferation and tissue homeostasis in epithelial stem cell 2 
compartments. In the liver, metabolic zonation requires a Wnt/β-Catenin signalling 3 
gradient, but the instructive mechanism controlling its spatiotemporal regulation is 4 
not known. We have identified a novel role for the RSPO-LGR4/5-ZNRF3/RNF43 5 
module as master regulator of Wnt/β-Catenin-mediated metabolic liver zonation. 6 
Liver-specific LGR4/5 loss-of-function (LOF) or RSPO blockade disrupted hepatic 7 
Wnt/β-Catenin signalling and zonation. Conversely, pathway activation in 8 
ZNRF3/RNF43 LOF mice or with recombinant RSPO1 protein expanded the hepatic 9 
Wnt/β-Catenin signalling gradient in a reversible and LGR4/5-dependent manner. 10 
Furthermore, we show that LGR4+ hepatocytes throughout the lobule contribute to 11 
liver homeostasis and regeneration. Likewise, recombinant RSPO1 protein increased 12 
liver size and improved liver regeneration, whereas LGR4/5 LOF caused the opposite 13 
effects, resulting in hypoplastic livers. Together, the RSPO-LGR4/5-ZNRF3/RNF43 14 
module controls metabolic liver zonation and acts as a hepatic growth/size rheostat 15 
during development, homeostasis and regeneration. 16 
 17 
Hepatic zonation and organ size control are required for physiological liver function, 18 
including metabolization of a wide range of endogenous products and xenobiotics. 19 
Hepatocyte function is determined by its position along the porto-central axis of the 20 
liver lobule, which creates a metabolic zonation in the liver. Complementary metabolic 21 
pathways occur within non-overlapping liver zones, thus maintaining optimal metabolic 22 
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homeostasis 1-5. Physiological liver size is tightly controlled by the concerted growth of 1 
hepatocytes and other hepatic cells during development, homeostasis and regeneration 2 
6-8. Recent studies have highlighted the Wnt/β-Catenin pathway as a major regulator of 3 
liver zonation, development and regeneration 4, 9-11. Wnt pathway activation stimulates 4 
cytoplasmic stabilization and nuclear translocation of β-Catenin, which subsequently 5 
associates with transcriptional regulators to control β-Catenin target gene expression 6 
(e.g. Axin2 and leukocyte cell-derived chemotaxin 2 (Lect2)) and expression of other 7 
Wnt/β-Catenin-dependent genes (e.g. Glutamine synthetase (GS) and Cyp2e1) 12. β-8 
Catenin-deficient mouse livers exhibit defects in metabolic liver zonation 10. The 9 
Adenomatous polyposis coli (APC) protein antagonizes β-Catenin activity, since APC 10 
deletion activates β-Catenin signalling and thereby expands the hepatic Wnt activity 11 
gradient 9, 13. Deletion of β-Catenin impaired hepatocyte proliferation during liver 12 
development and regeneration, whereas transgenic β-Catenin overexpression or APC 13 
deletion results in hyperplastic livers and hepatocellular carcinoma due to increased 14 
hepatocyte proliferation 14-19. However, the instructive molecular cues for 15 
spatiotemporal control of Wnt/β-Catenin signalling in liver zonation, development and 16 
regeneration have remained elusive.  17 
R-Spondin (RSPO)1-4 ligands potentiate Wnt/β-Catenin signalling via Leucine-rich repeat 18 
containing G protein-coupled receptors 4-6 (LGR4-6) 20-23. In the absence of RSPO 19 
proteins, Wnt signal transduction is negatively regulated by cell-surface transmembrane 20 
E3 ubiquitin ligases, Zinc and ring finger 3 (ZNRF3) and its homologue Ring finger 43 21 
(RNF43), which both promote Wnt receptor turnover. Upon stimulation, RSPO proteins 22 
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bind to LGR4/5 receptors as well as the ZNRF3/RNF43 transmembrane ubiquitin ligases, 1 
causing the latter to become cleared from the plasma membrane which leads to 2 
increased Wnt signalling 24, 25. We and others have shown that RSPO-LGR4/5-3 
ZNRF3/RNF43 signalling plays an essential role in developing and maintaining various 4 
epithelial tissue stem cell compartments by regulating tissue homeostasis 21, 23, 26, 27. The 5 
liver has a remarkable plasticity with an intrinsically high capacity for context-dependent 6 
regeneration in response to diverse injuries and during homeostasis 28-32. LGR5 has been 7 
reported to be exclusively expressed around the portal vein only following injury 33, 34, 8 
whereas undamaged livers have persistent high Wnt/β-Catenin activity around the 9 
central vein 1, 35. This is in contrast to other tissues where cells with high Wnt/β-Catenin 10 
activity express LGR4 and LGR5 to mediate RSPO-mediated Wnt/β-Catenin signalling 21, 11 
23, 26, 27. A potential role of RSPO-LGR4/5-ZNRF3/RNF43 signalling in the regulation of 12 
hepatic Wnt/β-Catenin activity during liver development, homeostasis and regrowth has 13 
remained unclear. 14 
Through integrated in vivo approaches comprising lineage tracing, tissue-specific LGR4/5 15 
LOF, pathway activation via RSPO1 injections or ZNRF3/RNF43 LOF and RNA expression 16 
analyses we have identified a novel role for the RSPO-LGR4/5-ZNRF3/RNF43 module in 17 
controlling metabolic liver zonation. We further show that the RSPO-LGR4/5-18 
ZNRF3/RNF43 module acts as a hepatic growth/size rheostat during development, 19 
homeostasis and regeneration and that recombinant RSPO1 protein administration 20 
accelerates liver regrowth. 21 
 22 
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LGR4 and LGR5 are co-expressed in pericentral hepatocytes with high Wnt activity 1 
To gain a detailed resolution of the hepatic Wnt/β-Catenin signalling gradient regulating 2 
metabolic liver zonation, we assessed Wnt/β-Catenin activity in different hepatic zones 3 
using immunostaining, in situ hybridization (ISH) and transgenic reporter mice. 4 
Expression of GS, a Wnt/β-Catenin-dependent gene and key enzyme in the ammonia 5 
detoxification pathway 10 (Figure 1a, 1c) as well as β-Catenin reporter activity in Tcf/Lef-6 
Venus mice 36 (Figure 1b, 1c), were restricted to the first layers of hepatocytes around 7 
the central vein. Similarly, ISH showed that Axin2 mRNA was predominantly expressed 8 
in these cells (Figure 1d, 1e). Expression of CYP2E1, another metabolic enzyme and 9 
Wnt/β-Catenin-dependent gene 37, extended into the parenchyma adjacent to the 10 
central veins (Figure 1a, 1c). This suggests differential expression of Wnt/β-Catenin-11 
dependent genes along the centro-portal Wnt/β-Catenin signalling gradient possibly 12 
because of different inductive thresholds or transcriptional regulation for these genes. 13 
To explore whether the RSPO receptors LGR4 and LGR5 and the ubiquitin ligases ZNRF3 14 
and RNF43 contribute to the regulatory network that establishes the Wnt/β-Catenin 15 
signalling gradient and liver zonation, we performed a detailed expression analysis. 16 
Using ISH staining in wild type mice, we found Lgr5 expression mainly restricted to 17 
pericentral hepatocytes with high Wnt activity. Almost all hepatocytes adjacent to the 18 
central vein, mono- and bi-nucleated, expressed Lgr5. The number of Lgr5-positive 19 
hepatocytes slightly decreased in the 2nd and 3rd pericentral layers, whereas only a 20 
negligible minority of parenchymal hepatocytes expressed Lgr5. Lgr4, which was 21 
coexpressed with Lgr5 in pericentral hepatocytes, was expressed in virtually all 22 
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hepatocytes across the liver lobule (Figure 1f, 1g; Supplementary Figure 1a, 1b).  Znrf3 1 
was broadly expressed in hepatocytes throughout liver (Figure 1h, 1i), whereas mice 2 
that express LacZ from the Rnf43 locus (Supplementary Figure 2a) showed that Rnf43 3 
expression was restricted to central vein hepatocytes (Figure 1j, 1k), similar as seen for 4 
Lgr4 and Lgr5, respectively. To further explore the expression profiles and roles of Lgr4 5 
and Lgr5 in the liver, we performed lineage tracing experiments using mice expressing 6 
tamoxifen (TAM)-inducible Cre (CreERT2) from the Lgr4 (Lgr4ki mice) or Lgr5 (Lgr5ki 7 
mice) loci 26, crossed with Rosa26 (R26)-β-Galactosidase (β-Gal; LacZ) 38, R26-tdTomato 8 
(tdTOM) or R26-enhanced green fluorescent protein (EGFP) reporter mice 9 
(Supplementary Figure 3a). Ten-day lineage tracing in Lgr4ki/R26-LacZ mice labelled 10 
hepatocytes throughout the liver, confirming broad LGR4 expression (Figure 2a, 11 
Supplementary Figure 3b). Ten-month LGR4 lineage tracing in these mice showed a 12 
similar expression pattern with small LacZ+ hepatocyte clones consisting of 1-5 cells, in 13 
line with low rates of homeostatic cell division 5 (Figure 2b, 2c, Supplementary Figure 14 
3b). Similarly sized clones of LGR4 lineage-traced pericentral, parenchymal and 15 
periportal hepatocytes are indicative of similar proliferation rates within the 3 different 16 
liver zones (Figure 2c). Ten-day lineage tracing in Lgr5ki/R26-LacZ mice confirmed that 17 
LGR5 expression is restricted to pericentral hepatocytes (Figure 2d, Supplementary 18 
Figure 3c). Eighteen-month lineage tracing and distributions analysis across different 19 
zones indicated that LGR5+ hepatocytes remained at the central vein as small clones 20 
consisting of 1-5 cells and do not radiate out into the parenchyma (Figure 2e, 2f, 21 
Supplementary Figure 3c, 3d). Co-expression of Axin2 and Lgr5 in virtually all of the 22 
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LGR5 lineage-traced hepatocytes, as measured by ISH, confirmed active Wnt signalling 1 
in these cells similar as in untraced neighbouring pericentral hepatocytes 2 
(Supplementary Figure 3e-g). Moreover, Ki67 staining in the LGR5 lineage-traced 3 
hepatocytes 48 h post-partial hepatectomy (PH) indicated that the proliferation capacity 4 
of these cells was similar compared to untraced neighbouring pericentral hepatocytes 5 
(Supplementary Figure 3h-j). A comparative 7-day EdU proliferation analysis in Lgr5ki 6 
and wt mice showed that the absence of one of the Lgr5 alleles did not impair 7 
homeostatic proliferation of pericentral hepatocytes (Figure 2i, 2j). Ten-day lineage 8 
tracing in Lgr4ki/R26-EGFP mice (Figure 2g) and Lgr5ki/R26-tdTOM mice (Figure 2h) and 9 
co-staining of labelled cells with hepatocyte markers Hepatocyte Nuclear Factor 4 Alpha 10 
(HNF4α) or GS, respectively, confirmed that the traced cells were indeed hepatocytes. In 11 
gut and skin, LGR4 is more broadly expressed than LGR5, and LGR5 expression is 12 
restricted to tissue stem cells with high Wnt activity. Concurrently, LGR5 is a Wnt target 13 
gene itself 39-41. Similarly, we observed a broad expression of LGR4 in hepatocytes 14 
throughout the liver, while LGR5 expression was restricted to pericentral hepatocytes 15 
with high Wnt activity. Despite persistent high Wnt activity and LGR5 expression, 16 
pericentral hepatocytes rarely proliferated and did not exhibit increased proliferation 17 
rates when compared to those of other hepatic zones, as indicated both by EdU 18 
labelling (Figure 2i, 2k-m and Supplementary Figure 3k-n) and Ki67 staining (Figure 2n-19 
p). This is in contrast to actively cycling LGR5+ cells in tissue stem cell compartments of 20 
other organs 27, but consistent with similar homeostatic proliferation rates across 21 
different liver zones reported earlier 42. In undamaged livers, the majority (>80%) of 22 
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proliferating cells were found in the liver parenchyma (Figure 2m, 2p, and 1 
Supplementary Figure 3n), itself the largest hepatic zone, indicating that parenchymal 2 
hepatocytes account for the majority of new hepatocytes during liver homeostasis. This 3 
is consistent with previous reports showing that the majority of proliferating 4 
hepatocytes reside in the parenchyma and that hepatocytes throughout the lobule 5 
contribute to liver homeostasis without zonal dominance 42-44. 6 
 7 
LGR4 and LGR5 receptors are essential for metabolic liver zonation 8 
To delineate whether LGR4 and LGR5 are mediating the instructive cues that establish 9 
the hepatic Wnt/β-Catenin signalling gradient and liver zonation, we generated liver-10 
specific Lgr4 knock-out (KO) (Lgr4LKO), Lgr5KO (Lgr5LKO) and Lgr4/5 double KO 11 
(Lgr4/5dLKO) mice using Albumin (Alb)Cre-mediated deletion (Supplementary Figure 12 
2b). Mice of all 3 genotypes were born at normal Mendelian ratios and viable with 13 
normal lifespans (data not shown). Lgr4LKO and Lgr4/5dLKO, but not Lgr5LKO mice 14 
showed reduced liver weight when compared to control mice (Figure 3a). Loss of Lgr4 15 
and Lgr5 mRNA in the liver was confirmed by reverse transcription polymerase chain 16 
reaction (RT-PCR) (Figure 3b) and ISH (Figure 3c). While no overt changes were observed 17 
in Lgr5LKO mice, Wnt signalling was abrogated in Lgr4/5dLKO and Lgr4LKO mice, as 18 
indicated by loss of Axin2 and Lect2 expression. Lgr5 mRNA expression was absent in 19 
Lgr4LKO mice (Figure 3b, 3c), similar as we previously reported for the developing 20 
intestinal epithelium 26. This suggests a dominant role for LGR4 over LGR5, and that loss 21 
of Lgr5 expression is a result of abrogated Wnt signalling. GS staining was severely 22 
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reduced in Lgr4LKO and completely lost in Lgr4/5dLKO mice, whereas Lgr5LKO mice had 1 
slightly elevated GS expression when compared to control mice (Figure 3d, 3e). 2 
Likewise, LGR4 and LGR4/5 deletion resulted in impaired CYP2E1 expression (Figure 3f, 3 
3g).  Early postnatal analysis of Lgr4/5dLKO mice showed reduced GS expression already 4 
at postnatal day (P)2 which remained low on P10 and P30, whereas it was increased in 5 
control mice from P2 to P10 (Supplementary Figure 4a, 4b). P2, P10 and P30 Lgr4/5dLKO 6 
mice showed functional hepatocyte and biliary cell differentiation during liver 7 
development, as evidenced by normal distribution of HNF4α+ hepatocytes, SRY (Sex 8 
Determining Region Y)-Box 9 (SOX9)+/Cytokeratin 19 (CK19)+ biliary ducts and absence 9 
of SOX9 in hepatocytes (Supplementary Figure 4c, 4d), excluding the possibility that 10 
compromised hepatocyte differentiation during liver development accounts for the 11 
impaired metabolic zonation. To gain further insights into the mechanistic 12 
consequences of liver-specific LGR4/5 deletion, we performed high-throughput RNA 13 
sequencing (RNA-Seq) on total liver RNA samples isolated from control and Lgr4/5dLKO 14 
mice. Expression of Wnt target genes (e.g. Axin2, Lect2 and Tumor Necrosis Factor 15 
Receptor Superfamily, Member 19 (Tnfrsf19; Troy)) as well as gene sets for Wnt 16 
signalling and metabolic processes were significantly downregulated in livers with 17 
combined LGR4 and LGR5 deletions (Supplementary Figure 5a, 5b, Supplementary Table 18 
1, 2). Comparative expression analysis of genes encoding for metabolic enzymes 45 19 
revealed that pericentrally expressed metabolic genes were downregulated, whereas 20 
few periportal genes (Hsd17b13 and Hal) were upregulated in Lgr4/5dLKO compared to 21 
control mice (Figure 3h, Supplementary Figure 5a). RT-PCR analysis confirmed 22 
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downregulation of pericentral metabolic genes (Glul, Cyp2e1 and Cyp1a2) and 1 
upregulation of Hsd17b13 and Hal (Figure 3i, 3j). This indicates that loss of hepatic 2 
Wnt/β-Catenin signalling in Lgr4/5dLKO mice results in loss of metabolic liver zonation. 3 
RT-PCR and immunostaining confirmed that periportal metabolic genes, that were 4 
upregulated in β-Catenin KO mice or mice with virus-mediated DKK1 overexpression 9, 13, 5 
were not upregulated in Lgr4/5dLKO compared control mice (Figure 3j; Supplementary 6 
Figure 5c, 5d). It is possible that inactivation or deletion of Wnt pathway components at 7 
different hierarchical levels result in distinct signalling output events which might 8 
account for these differences; e.g. LGR4/5 deletion was also shown to impair non-9 
canonical Wnt signalling, in contrast to β-Catenin deletion or DKK1 overexpression 22, 46. 10 
Moreover, downregulated gene sets involved in cell cycle regulation further suggest a 11 
role for LGR4 and LGR5 in controlling hepatic cell proliferation (Supplementary Figure 12 
5b). Together, we identified an essential role for LGR4 and LGR5 receptors in spatial 13 
regulation of the centro-portal Wnt/β-Catenin signalling gradient and metabolic liver 14 
zonation.  15 
 16 
RSPO controls liver zonation via LGR4 and LGR5 receptors 17 
Overexpression of the extracellular domain (ECD) of ZNRF3 (ZNRF3ECD) was shown to 18 
block endogenous RSPO function by blocking RSPO1-induced membrane accumulation 19 
of Frizzled proteins 24. To analyse whether RSPO proteins control the hepatic Wnt/β-20 
Catenin signalling gradient, we generated BAC-transgenic mice that allow doxycycline 21 
(DOX)-induced ubiquitous expression of the ZNRF3ECD (Znrf3ECD mice) and crossed 22 
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these mice with Axin2-LacZ mice to obtain double transgenic Znrf3ECD/Axin2-LacZ mice 1 
(Figure 4a). Znrf3ECD/Axin2-LacZ mice fed with DOX-containing diet showed reduced 2 
LacZ expression when compared to those with normal diet, indicating that loss of 3 
endogenous RSPO function impaired the hepatic Wnt/β-Catenin activity gradient (Figure 4 
4b, 4c). Likewise, GS (Figure 4d, 4e) and CYP2E1 (Figure 4f, 4g) expression was 5 
dramatically reduced in Znrf3ECD/Axin2-LacZ mice fed with DOX-containing diet. We 6 
next generated mice that allowed for the inducible combined deletion of ZNRF3 and 7 
RNF43 using TAM (Znrf3/Rnf43dfl;R26CreERT2 mice) (Figure 4h). TAM injections 8 
resulted in a dramatic increase in GS (Figure 4i, 4j) and CYP2E1 (Figure 4k, 4l) expression 9 
in Znrf3/Rnf43dfl;R26CreERT2 mice when compared to Znrf3/Rnf43dfl;R26CreERT2 mice 10 
without TAM, with CYP2E1 expression even expanding into portal vein hepatocytes 11 
(Figure 4k). This indicates that the LGR4/5-ZNRF3/RNF43 complex is a key regulator of 12 
the hepatic Wnt/β-Catenin signalling gradient and metabolic liver zonation. 13 
To further study the effect of RSPO in liver zonation, we administered recombinant 14 
RSPO1 (10 mg/kg) or PBS twice weekly to Lgr4/5dLKO and control mice for 1 week, 2 15 
weeks and 2 weeks followed by 4 weeks off-treatment (wash-out) (Figure 5a). 2 weeks 16 
RSPO1 injection in adult wild type mice and 2 weeks RSPO1 injection in TCF/LEF-Venus 17 
mice markedly increased Axin2 mRNA (Figure 5b, 5c) and Wnt/β-Catenin reporter 18 
expression (Figure 5d, 5e), respectively. Importantly, RSPO1 injections expanded Wnt/β-19 
Catenin signalling into periportal hepatocytes, indicating that all cells across the liver 20 
lobule are competent to respond to Wnt pathway activation and that Wnt receptors and 21 
ligands must be available throughout the liver. Likewise, RSPO injections increased GS 22 
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protein (Figure 5f, 5g) and CYP2E1 protein (Figure 5h, 5i) expression in control mice but 1 
not in Lgr4/5dLKO mice when compared to PBS injected mice after 1 week. After 2 2 
weeks, additional RSPO1 injections further expanded GS and CYP2E1 expression, which 3 
were reduced to PBS control levels after additional 4 weeks off-treatment (Figure 5f-i).  4 
This further indicates that RSPO1 controls hepatic Wnt/β-Catenin signalling in an 5 
LGR4/5-dependent manner to confer spatiotemporal regulation of the centro-portal 6 
Wnt/β-Catenin activity gradient and metabolic liver zonation. It also indicates that 7 
sustained signalling through the RSPO-LGR4/5-ZNRF3/RNF43 module is essential to 8 
maintain this zonation. Notably, RSPO1 injections or ZNRF3/RNF43 deletions did not 9 
result in immediate ectopic GS expression throughout the liver but caused progressing 10 
expansion along the centro-portal axis, similarly to what was observed in Apc mutant 11 
mice 13. This suggests the possibility that other mechanisms contribute to regulating 12 
zonated GS expression; e.g. YAP activity in periportal hepatocytes may restrict GS 13 
expression, as it was recently shown that YAP is expressed in a porto-central gradient 14 
and can negatively regulate GS 47, 48. In summary, our data suggest that Wnt receptors 15 
and ligands are distributed throughout the liver lobule and that the RSPO-LGR4/5-16 
ZNRF3/RNF43 module is essential for hepatic Wnt signalling and metabolic liver 17 
zonation. 18 
 19 
LGR4 and LGR5 deletions impair postnatal liver development 20 
Reduced liver weight and downregulation of gene sets involved in cell cycle regulation 21 
indicated impaired growth control in Lgr4/5dLKO mice. Analysis of early postnatal 22 
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development revealed impaired hepatocyte proliferation in Lgr4/5dLKO mice at P2 and 1 
P10, whereas no significant difference was observed at P30 with overall reduced 2 
proliferation rates (Supplementary Figure 6a-c), as well as in adult mice (data not 3 
shown) when compared to control littermates. Notably, impaired proliferation was most 4 
evident in pericentral hepatocytes with high Wnt activity. Consequently, liver weight 5 
was significantly reduced in P10 and P30 Lgr4/5dLKO mice when compared to control 6 
mice, while it was comparable at P2 among both genotypes (Supplementary Figure 6d). 7 
To study whether LGR4 and LGR5 are important for controlling proliferation during 8 
embryonic liver development we stained E16.5 embryos with full-KO for LGR4, LGR5 and 9 
LGR4/5 as well as wild type littermates 26 for Ki67. We did not observe any differences in 10 
the proliferative capacity of the liver between the different genotypes (Supplementary 11 
Figure 6e, 6f), indicating that LGR4 and LGR5 are dispensable for embryonic liver growth 12 
at E16.5. This suggests that reduced liver weight in Lgr4/5dLKO mice is a consequence of 13 
impaired hepatocyte proliferation during later stages of liver development.  14 
 15 
RSPO controls liver size and regeneration via LGR4/5 receptors 16 
Impaired liver development and liver size in Lgr4/5dLKO mice suggested that RSPO-17 
LGR4/5 signalling might act as a hepatic growth/size rheostat. To further investigate this 18 
mechanism, we subjected Lgr4LKO, Lgr5LKO, Lgr4/5dLKO and control mice to PH (Figure 19 
6a). 2 days post-PH, liver weight was significantly reduced in Lgr4LKO and Lgr4/5dLKO 20 
but not in Lgr5LKO mice when compared to controls (Figure 6b). Detailed proliferation 21 
analysis by Ki67 immunostaining revealed that Lgr4LKO, Lgr5LKO and Lgr4/5dLKO mice 22 
14 
 
showed impaired proliferation in pericentral hepatocytes (Figure 6c). In contrast, 1 
proliferation of parenchymal (Figure 6d) and periportal (Figure 6e) hepatocytes was only 2 
impaired in Lgr4LKO and Lgr4/5dLKO but not in Lgr5LKO mice when compared to control 3 
mice. Zonal differences in proliferation indicate that LGR receptors are required for 4 
proliferation in their respective expression zones. Interestingly, during the peak 5 
regenerative response post-PH in control mice, hepatocyte proliferation rates were 6 
generally lower around the central vein when compared to portal vein and parenchyma 7 
(Figure 6c-e). RT-PCR for Axin2 showed activation of the Wnt pathway during liver 8 
regeneration (d2 post-PH) in control mice and confirmed lack of Axin2 expression in 9 
Lgr4/5dLKO mice (Figure 6f). Moreover, Axin2 ISH showed a global increase in Wnt/β-10 
Catenin signalling that extended to periportal hepatocytes at d2 post-PH 11 
(Supplementary Figure 7a, 7b), similar as seen in mice with RSPO1 injections. 12 
The above findings indicate that LGR4/5 LOF impaired hepatocyte proliferation during 13 
liver regeneration as a consequence of abrogated Wnt signalling. It was recently shown 14 
that liver progenitor markers, including Lgr5, were upregulated d2 post-PH in periportal 15 
hepatocytes 34. While RNA-Seq analysis confirmed upregulation of progenitor markers 16 
(Krt7, Tnfsrf12a) in control mice d2 post-PH when compared to naïve controls, Lgr5 17 
expression was not increased (Supplementary Figure 7c). ISH analysis confirmed that 18 
Lgr5 was neither upregulated nor expressed in periportal hepatocytes of control mice at 19 
d2 post-PH. Similarly, Lgr4 ISH signals were not increased d2 post-PH (Supplementary 20 
Figure 7d-f). RNA-Seq of Lgr4/5dLKO compared to control livers at d2 post-PH further 21 
showed no change in liver progenitor marker expression (Sox9, Afp, Tnfsrf12a, Krt7, 22 
15 
 
Krt19; Supplementary Figure 7g), suggesting that these cells did not contribute to 1 
impaired regeneration in Lgr4/5dLKO mice.  RNA-Seq analysis further revealed that 2 
expression of Wnt target genes and genes regulating cell cycle progression and 3 
metabolism were reduced in Lgr4/5dLKO compared to control livers at d2 post-PH 4 
(Figure 6g). Likewise, gene sets implicated in cell cycle regulation and metabolism were 5 
downregulated in livers of regenerating Lgr4/5dLKO mice (Figure 6h). To study whether 6 
Lgr4/5LKO mice suffer from delayed liver regeneration, we additionally assessed 7 
hepatocyte proliferation during later stages of liver regeneration at d4 and d7 post-PH 8 
by Ki67 immunostaining (Figure 6i). Both at d4 and d7 hepatocyte proliferation was 9 
significantly increased in Lgr4/5LKO when compared to control mice (Figure 6j), similar 10 
to the delayed onset of proliferation seen in β-Catenin KO mice 14. Despite increased 11 
proliferation at later phases of liver regeneration, Lgr4/5dLKO mice showed significant 12 
impairment in the magnitude and effectiveness of the regenerative response, resulting 13 
in a smaller final liver to body weight ratio compared to control mice (Figure 6k). This 14 
indicates that LGR4/5 are essential for the Wnt/β-Catenin-mediated early regenerative 15 
response which is required for establishing a normal liver to body weight ratio during 16 
regeneration, similar to our observations during liver development and homeostasis. 17 
Lineage tracing in Lgr5ki/R26-LacZ mice following PH indicated that pericentral LGR5+ 18 
hepatocytes do not extensively populate the liver during regrowth (Supplementary 19 
Figure 7h, 7i). Together, these findings highlight an important role for LGR4 and LGR5 in 20 
hepatocyte proliferation and liver size control during regeneration, with a dominant role 21 
for LGR4. Moreover, complete absence of Wnt/β-Catenin signalling in mice with LGR4/5 22 
16 
 
deletions established that the RSPO-LGR4/5-ZNRF3/RNF43 module is an essential 1 
mediator rather than a sole potentiator of Wnt/β-Catenin activity. 2 
To study the role of RSPO in hepatic size control, we administered recombinant RSPO1 3 
(10 mg/kg) or PBS twice weekly to Lgr4/5dLKO and control mice for 1 week, 2 weeks and 4 
2 weeks followed by 4 weeks off-treatment (see scheme in Figure 5a). 1 week RSPO1 5 
treatment in control mice significantly increased hepatocyte proliferation in all 3 liver 6 
zones when compared to PBS-injected control mice, with the strongest proliferative 7 
response in periportal hepatocytes. In Lgr4/5dLKO mice, RSPO1 did not increase 8 
hepatocyte proliferation (Figure 7a, 7b). Consequently, RSPO1 treatment in control mice 9 
resulted in increased liver weight when compared to PBS-injected mice, further 10 
increasing with prolonged treatment and decreasing upon RSPO1 withdrawal. In 11 
contrast, Lgr4/5dLKO mice did not gain liver weight following RSPO1 treatment (Figure 12 
7c). Together, this indicates that RSPO1 increases liver size in a reversible and Lgr4/5-13 
dependent manner. Likewise ZNRF3/RNF43 deletion in Znrf3/Rnf43dfl;R26CreERT2 mice 14 
resulted in a dramatic increase in hepatocyte proliferation 11 days post-TAM injections 15 
when compared to Znrf3/Rnf43dfl;R26CreERT2 mice without TAM (Figure 7d, 7e), 16 
showing a similar zonal profile as in RSPO1-injected mice. Increased proliferation of 17 
hepatocytes throughout the liver following ZNRF3/RNF43 deletions highlights the 18 
importance of these E3 ubiquitin ligases in restricting hepatocyte proliferation during 19 
liver homeostasis and suggests broad availability of Wnt receptors and ligands 20 
throughout the liver. Proliferation induced by RSPO1 injections or ZNRF3/RNF43 21 
deletions was most evident in periportal hepatocytes, whereas Wnt/β-Catenin activity 22 
17 
 
was higher in pericentral and parenchymal hepatocytes in RSPO1-injected mice. It is 1 
therefore possible that other pathways might cooperate with Wnt/β-Catenin to mediate 2 
this phenotype. 3 
Finally, we assessed the potential of recombinant RSPO1 for improving liver 4 
regeneration. We therefore injected control mice with 10 mg/kg RSPO1 on 2 5 
consecutive days, subjected the mice to PH and monitored liver regrowth by MRI (Figure 6 
7f). While liver weight was not changed during the early phase (d2) of regeneration in 7 
either PBS- or RSPO1-injected mice, the latter showed a significant increase in liver 8 
weight at d7 post-PH (Figure 7g). Consistently, an MRI time-course showed increased 9 
liver size in RSPO1-injected mice during late phase regeneration (d6, d7) beyond levels 10 
of PBS-injected mice, whereas it was not changed before PH or at early stages of liver 11 
regeneration (Figure 7h, i). This indicates that increased RSPO1 levels overrule liver size 12 
control during regeneration. Most importantly, RSPO1 treatment accelerated liver 13 
regeneration since RSPO1-treated mice reached the final liver volume of control mice 14 
more rapidly. Together, RSPO-LGR4/5-ZNRF3/RNRF43 signalling acts as a hepatic 15 
growth/size rheostat during development, homeostasis and regeneration. 16 
 17 
Discussion 18 
Our data support a novel role for RSPO-LGR4/5-ZNRF3/RNF43 signalling in controlling 19 
spatiotemporal regulation of the hepatic Wnt/β-Catenin activity gradient and metabolic 20 
liver zonation. Impaired liver zonation in Lgr4/5dLKO mice is phenocopied in Znrf3ECD 21 
mice, whereas RSPO1 administration expanded the hepatic Wnt gradient in a reversible 22 
18 
 
and LGR4/5-dependent manner. A recent study suggested that Wnt9b confers Wnt/β-1 
Catenin activity restricted to the central vein 31. We now found that RSPO1 injections or 2 
ZNRF3/RNF43 deletions expanded Wnt/β-Catenin activity to periportal hepatocytes, 3 
indicating that Wnt receptors and ligands are available throughout the liver. Moreover, 4 
Wnt9b deletion only reduced Wnt/β-Catenin activity 31 while LGR4/5 deletion resulted 5 
in complete loss of hepatic Wnt/β-Catenin signalling. This indicates that the RSPO-6 
LGR4/5-ZNRF3/RNF43 module is not just potentiating Wnt activity but is essential for 7 
functional Wnt/β-Catenin signalling in the liver. While our data suggest that RSPO 8 
proteins confer local restriction of hepatic Wnt activity, their source and distribution 9 
remain to be identified.  10 
The strongest increase in RSPO-induced proliferation around the portal vein was not 11 
paralleled by highest Wnt/β-Catenin activity in the region, indicating that other 12 
pathways might contribute to this phenotype. It was recently shown that YAP 13 
expression shows an inverse gradient to Wnt/β-Catenin activity in the liver 47. Moreover, 14 
Wnt/β-Catenin activation promotes YAP signalling in other tissues 49. It is possible that 15 
Wnt/β-Catenin-mediated YAP activation may contribute to periportal hepatocyte 16 
proliferation. 17 
In a variety of tissue stem cell compartments, LGR4+ and LGR5+ cells are actively cycling 18 
and give rise to more mature cells with a high turnover 39-41. Unlike other LGR5+ 19 
epithelial cells, pericentral LGR5+ hepatocytes did neither show overt proliferation nor 20 
gave rise to hepatocytes distant to the central vein, either under homeostasis conditions 21 
within an observation period of 18 months or during a 7-day post-PH liver regeneration 22 
19 
 
period. Moreover, our EdU and Ki67 analyses in wild type mice could not detect 1 
increased proliferation of pericentral hepatocytes when compared to those of other 2 
liver zones. Our findings did not support the results of a recent study that was published 3 
during revision of our manuscript 31. The authors proposed that pericentral hepatocytes 4 
comprise liver stem cells that repopulate large parts of the liver during homeostasis, 5 
whereas their potential during regeneration was not assessed31. Another recent study 6 
suggested that periportal hepatocytes with low SOX9 expression levels are liver stem 7 
cells with high regenerative capacity during homeostasis and drug-induced liver damage 8 
caused by zonal injury at the central vein 29. It has been speculated that the site of injury 9 
determines the site of regeneration and that hepatocytes in different hepatic zones may 10 
mutually support liver regeneration in opposing sides 28. Studying homeostatic 11 
hepatocyte renewal or regenerative response to PH, a paradigm model for liver 12 
regeneration that is not biased by zonal injury, we now show that LGR4+ hepatocytes 13 
throughout the liver contribute to liver homeostasis and regeneration. While the 14 
majority (>80%) of proliferating hepatocytes during homeostasis was found in the 15 
parenchyma, proliferation rates between the 3 zones were similar. During the peak 16 
regenerative response post-PH, pericentral hepatocytes proliferated less than 17 
parenchymal and periportal hepatocytes. Our findings are consistent with previous 18 
reports showing no zonal domination during liver homeostasis and reduced proliferation 19 
of pericentral hepatocytes following PH 42, 50. This supports that parenchymal 20 
hepatocytes can have similar regenerative capacity as pericentral or periportal 21 
hepatocytes. Our data add to the emerging concept that there might not be just one 22 
20 
 
liver stem cell compartment but that cells in different liver zones show increased 1 
regenerative potential depending on the injury 28, 32.  2 
Despite recent advances in identifying cellular compartments that contribute to liver 3 
regeneration and maintenance 28-30, 32, 34, 44, the detailed mechanisms that confer 4 
spatiotemporal control of proliferation to maintain proper liver size remained elusive. 5 
We now show that increased RSPO-LGR4/5-ZNRF3/RNF43 signalling overrules the stop 6 
signals during liver regrowth or homeostasis, whereas LGR4/5 deletions result in 7 
hypoplastic livers. Likewise, LGR4/5 deletions impair liver regeneration, whereas RSPO1 8 
injections accelerate regeneration. This supports the notion that the RSPO-LGR4/5-9 
ZNRF3/RNF43 module acts as rheostat controlling liver growth and size. Our data 10 
further highlight important roles of ZNRF3 and RNF43 in restricting proliferation in the 11 
liver, consistent with Rnf43 mutations observed in liver tumours 51.  12 
Recently, periportal LGR5+ progenitor cells with bipotential progenitor characteristics 13 
were identified following CCl4 liver damage or diets that resulted in oval cell response in 14 
mice 33. In contrast to our study, no LGR5+ cells were found in livers of naïve mice. It is 15 
possible that different genetic backgrounds between the mice used in our study (pure 16 
C57Bl/6) and those used in the above study (mixed C57Bl/6-Balb/c F1), different TAM 17 
dosing regimens or partial hepatic transgene silencing, as previously reported 33, 52, 18 
could explain these differences. 19 
In contrast to LGR5, which was restricted to pericentral hepatocytes with high Wnt/β-20 
Catenin pathway activity, LGR4 was broadly expressed in hepatocytes throughout the 21 
liver. Moreover, LGR5 has been described as a Wnt/β-Catenin target 39-41. LGR5 deletion 22 
21 
 
impaired pericentral hepatocyte proliferation post-PH, and combined deletion of LGR4 1 
and LGR5 further impaired metabolic liver zonation than LGR4 deletion alone. This 2 
indicates that LGR5 is functionally relevant rather than just a marker of cells with high 3 
Wnt/β-Catenin activity. In contrast to LGR4 deletion, LGR5 deletion alone did not result 4 
in impaired Wnt/β-Catenin signalling. Loss of LGR5 expression as a consequence of LGR4 5 
deletion further suggests a dominant role of LGR4 over LGR5, as previously shown in 6 
other tissues 26. 7 
Our findings highlight novel roles for RSPO-LGR4/5-ZNRF3/RNF43 module in regulating 8 
Wnt/β-Catenin-mediated metabolic liver zonation and in acting as a growth/size control 9 
rheostat during liver development, homeostasis and regeneration. We further show 10 
that LGR4+ hepatocytes throughout the 3 liver zones contribute to homeostasis and 11 
regrowth. The growth-promoting effect of ectopic RSPO1 in livers highlights its potential 12 
use for regenerative therapies. 13 
 14 
 15 
Materials and Methods  16 
Immunostainings, ISH, RT-PCR and partial hepatectomy were essentially performed as 17 
described 53-55. Detailed information on MRI, RNA-Seq, recombinant RSPO1 protein 18 
generation, mouse model design, image analysis and statistical analysis is available in 19 
the supplementary online material and methods. The raw RNA-sequencing reads 20 
are available in the NCBI Short Read Archive under the accession number SRP055521. 21 
 22 
22 
 
Acknowledgements 1 
We thank Johann Wirsching, Carole Manneville, Marianne Lemaistre, Michel Haffner, 2 
Bettina Leonhard, Svenja Ley, Ning Guo, Tanya Lewis, Mei Li, Martin van de Velde, 3 
Daniel Breustedt, Hong Lei, Ryan Boomer, Stefan Zurbruegg, Ludovic Perrot, Francisco 4 
Cordoba, Sven Schuierer, Ana Arif and Julien Gfeller for technical assistance. For helpful 5 
discussion and critical reading of the manuscript we thank Elizabeth Wiellette, Gabi 6 
Hintzen, Bill Dietrich, Dong Liu, Frederic Bassilana, Christian Parker, Klaus Seuwen and 7 
Jeff Porter. This work was supported by the Leverhulme Trust ECF-2012-262 to Luke 8 
Boulter, SNF grant 310030B_147089 to Markus Heim, MRC Niche hub grant 9 
MR/K026666/1 to Stuart Forbes and the Novartis Institutes for BioMedical Research 10 
Program Office.  11 
 12 
Conflict of interest statement. All authors except SF, LB, LMT, MHH, DC and MTD are 13 
employed by and/or shareholders of Novartis Pharma AG. 14 
 15 
Figure legends 16 
Figure 1.  Lgr4 and Lgr5 are co-expressed in pericentral hepatocytes. a, GS and CYP2E1 17 
co-staining in control mice. b, Venus expression in Tcf/Lef-Venus mice. c, Percent of 18 
hepatocytes expressing GS, CYP2E1 and Tcf/Lef-Venus in 3 cell layers around central and 19 
portal veins and in the parenchyma. n = 5 mice per group. d, f, h, Axin2 (d), Lgr4 and 20 
Lgr5 (f) and Znrf3 (h) ISH in control mice. e, g, i, Axin2 (e), Lgr4 and Lgr5 (g), and Znrf3 (i) 21 
ISH quantified in the indicated liver zones. n = (e) 5 mice where 4225 cells from 75 22 
23 
 
images were quantified, (g) 4 mice per group where 3380 cells from 60 images were 1 
quantified, and (i) 5 mice where 4341 cells from 75 images were quantified. j, LacZ 2 
staining in Rnf43-LacZ mice. k, Percent of hepatocytes expressing Rnf43-LacZ in the 3 
indicated liver zones. n = 4 mice. cv, central vein; pv, portal vein. Scale bars, (a, b) 100 4 
µm, (magnification in a) 20 µm, (magnification in b) 50 µm, (d, f, h) 20 µm, 5 
(magnifications in d, f, h) 10 µm, (j) 100 µm and (magnifications in j) 50 µm.  6 
 7 
Figure 2. Lgr4 and Lgr5 lineage tracing during liver homeostasis.  a, b, LacZ staining in 8 
Lgr4ki/R26-LacZ mice showing LGR4+ hepatocytes after 10 days (a) or 10 months (b) of 9 
tracing. Arrowheads indicate clusters of LGR4+ hepatocytes. c, Clone size distribution of 10 
Lgr4ki/R26-LacZ+ hepatocytes. n = 3 mice. d, e, LacZ staining in Lgr5ki/R26-LacZ mice 11 
showing LGR5+ hepatocytes after 10 days (d) or 18 months (e) of tracing. Arrowheads 12 
(in b, e) indicate doublet cells. f, Clone size distribution of Lgr5ki/R26-LacZ+ hepatocytes. 13 
n = 4 mice. g, EGFP and HNF4α co-staining in Lgr4ki/R26-EGFP mice, showing 14 
EGFP+/HNF4α+ hepatocytes (arrowheads). h, tdTOM and GS co-staining in Lgr5ki/R26-15 
tdTOM mice, showing tdTOM+/GS+ hepatocyte (arrowhead). i, Scheme depicting EdU 16 
injections in WT and Lgr5ki mice. j, EdU+ pericentral hepatocytes quantified in WT and 17 
Lgr5ki mice. n = 6 mice where 2195 (WT) and 1591 (Lgr5ki) cells were quantified. k, GS 18 
and EdU co-staining in control mice. Arrowheads point at EdU+ hepatocytes. l, EdU+ 19 
hepatocytes quantified in liver zones of control mice (percentage of EdU+ hepatocytes 20 
among total number of hepatocytes in respective zones). n = 6 mice where 2195 (CV), 21 
3051 (PA) and 2555 (PV) cells from 90 images per zone were quantified. m, Distribution 22 
24 
 
of EdU+ hepatocytes in the indicated liver zones. n = 6 mice where 1296 cells were 1 
quantified. n, GS, biliary marker CK19 and Ki67 co-staining in control mice. Arrowheads 2 
point at Ki67+ hepatocytes. o, Ki67+ hepatocytes quantified in liver zones of control 3 
mice (percentage of Ki67+ hepatocytes among total number of hepatocytes in 4 
respective zones). p, Distribution of Ki67+ hepatocytes in the indicated liver zones. n = 4 5 
mice where 891 cells from 60 images were quantified. cv, central vein; pv, portal vein. 6 
ns, not significant. Scale bars, (a, b, d, e) 50 µm and (g, h, k, n) 20 µm.  7 
 8 
Figure 3. Lgr4 and Lgr5 receptors control liver zonation. a, Relative liver weight of the 9 
indicated mice. b, mRNA expression of different genes in the indicated mice. n = 5 mice 10 
per group. c, Lgr4 and Lgr5 ISH in the indicated mice. d, GS staining in the indicated 11 
mice. e, GS+ hepatocytes quantified in the indicated mice. f, CYP2E1 staining in the 12 
indicated mice. g, CYP2E1+ staining quantified in the indicated mice. h, Heatmap 13 
showing RNA expression of metabolic genes in livers of the indicated mice (yellow, high 14 
expression; blue, low expression). i, j, mRNA expression of pericentral (i) or periportal (j) 15 
metabolic genes in livers of the indicated mice. cv, central vein. n = 5 mice per group. *, 16 
P<0.05; **, P<0.01; ***, P<0.001; ****, P<0.0001; *****, P<0.00001. ns, not significant. 17 
Scale bars, (c) 20 µm, (d, f) 200 µm and (magnifications in d, f) 20 µm.  18 
 19 
Figure 4. ZNRF3 and RNF43 control liver zonation. a, Scheme depicting Znrf3ECD/Axin2-20 
LacZ mice that were given DOX or vehicle control on d1 and analysed on d7. b, d, f, LacZ 21 
(b), GS (d) or CYP2E1 (f) staining in Znrf3ECD/Axin2-LacZ mice +/- DOX. c, e, g, LacZ+ (c), 22 
25 
 
GS+ (e) or CYP2E1+ (g) staining quantified in Znrf3ECD/Axin2-LacZ mice +/- DOX. h, 1 
Scheme depicting Znrf3/Rnf43dfl;R26CreERT2 mice that were given TAM or vehicle 2 
control. i, k, GS (i) or CYP2E1 (k) staining in Znrf3/Rnf43dfl;R26CreERT2 mice +/- TAM. j, 3 
l, GS+ (j) or CYP2E1+ (l) staining quantified in Znrf3/Rnf43dfl;R26CreERT2 mice +/- TAM. 4 
cv, central vein; pv, portal vein. **, P<0.01; ***, P<0.001. Scale bars, (b) 100 µm, 5 
(magnifications in b) 50 µm, (d, f, i, k) 200 µm and (magnifications in d, f, i, k) 50 µm.  6 
 7 
Figure 5. RSPO1 controls liver zonation via Lgr4 and Lgr5 receptors. a, Scheme 8 
depicting control, Lgr4/5dLKO and Tcf/Lef-Venus mice that were injected i.v. with RSPO1 9 
or PBS for the indicated times. b, Axin2 ISH in control mice +/- RSPO1. c, Axin2 ISH 10 
quantified in control mice +/- RSPO1 in the indicated liver zones. n = 5 mice per group 11 
where 3392 cells (PBS) and 3774 cells (RSPO) from 75 images each were quantified. d, 12 
Venus expression in Tcf/Lef-Venus mice +/- RSPO1. e, Percent of Venus-expressing 13 
hepatocytes in Tcf/Lef-Venus mice +/- RSPO1 in the indicated liver zones. n = 4 mice 14 
(PBS) and 5 mice (RSPO). f, h, GS (f) and CYP2E1 (h) staining of control and Lgr4/5dLKO 15 
mice +/- RSPO1 for the indicated times. g, i, GS+ (g) or CYP2E1+ (i) staining quantified in 16 
control and Lgr4/5dLKO mice +/- RSPO1 for the indicated times. *, P<0.05; **, P<0.01; 17 
***, P<0.001; ****, P<0.0001; ns, not significant. Scale bars, (b) 20 µm, (magnifications 18 
in b) 10 µm, (d) 100 µm, (magnifications in d) 50 µm and (f, h) 200 µm.  19 
 20 
Figure 6. Loss of Lgr4 and Lgr5 results in impaired liver homeostasis and regeneration. 21 
a, Scheme depicting mice that were subjected to partial hepatectomy (PH) and analysed 22 
26 
 
at different time-points post-PH. b, Relative liver weight of the indicated mice at d2 1 
post-PH. c, d, e, Ki67 staining and pericentral (c), parenchymal (d) and periportal (e) 2 
hepatocyte proliferation of the indicated mice at d2 post-PH. f, Axin2 mRNA expression 3 
in livers of the indicated mice. n = 5 mice (control + PH and Lgr4/5dLKO + PH), 6 mice 4 
(control - PH) and 7 mice (Lgr4/5dLKO - PH). g, Volcano plot showing genes differentially 5 
expressed in livers of the indicated mice. h, Gene sets downregulated in livers of the 6 
indicated mice. i, Ki67 staining in livers of the indicated mice at d4 and d7 post-PH. j, 7 
Liver cell proliferation quantified in the indicated mice at d4 and d7 post-PH. k, Relative 8 
liver weight of the indicated mice at d2, d4 and d7 post-PH. *, P<0.05; **, P<0.01; ***, 9 
P<0.001; ns, not significant. Scale bars, 100 µm.  10 
 11 
Figure 7. RSPO1 promotes hepatocyte proliferation and liver regeneration via Lgr4 and 12 
Lgr5 receptors. a, Ki67 staining in livers of the indicated mice, showing Ki67+ 13 
hepatocytes (arrowheads). b, Hepatocyte proliferation quantified in liver zones of the 14 
indicated mice upon RSPO1 or PBS injection. c, Relative liver weight of the indicated 15 
mice. d, Ki67 staining in livers of the indicated mice, showing Ki67+ hepatocytes 16 
(arrowheads). e, Hepatocyte proliferation quantified in liver zones of the indicated mice. 17 
f, Scheme depicting control mice that were injected i.v. with RSPO1 or PBS on two 18 
consecutive days and subjected to PH. g, Relative liver weight of the indicated mice. h, 19 
Representative MRI liver sections of the indicated mice. i, Liver volume growth curve of 20 
the indicated mice following RSPO1 or PBS injection and PH. n = 6 male mice per group. 21 
27 
 
*, P<0.05; **, P<0.01; ***, P<0.001; ****, P<0.0001; ns, not significant. Scale bars, (a, d) 1 
50 µm and (h) 6 mm.  2 
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